The pharmaceutical distributor has launched InspiroGene, a business unit offering logistics and other support for ...

It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions ...

We rate McKesson as a 'Strong Buy' with focus on GLP-1 meds, oncology network, and strong Q2 results driving future growth.

McKesson's second-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical ...

McKesson (MCK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Allen Lutz ...

Morgan Stanley analyst Erin Wright has maintained their bullish stance on MCK stock, giving a Buy rating today. Erin Wright has given his Buy ...

Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company ...

Operator Ladies and gentlemen, welcome to McKesson's second quarter fiscal 2025 earnings conference call. Please be advised that today's conference is being recorded. At this time, I'd like to turn ...

McKesson Medical-Surgical Inc. entered into an agreement with the Labor Department on Monday resolving employment ...

Chicago Partners Investment Group LLC increased its stake in shares of McKesson Co. (NYSE:MCK – Free Report) by 17.0% during ...